Neogenomics Inc risk profile
62 Stretched several inputs deteriorating together
Measured 1 September 2026 from NEO's filed statements. Recomputed nightly.
62 (Stretched), driven by Cash conversion at 87, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 42 | Elevated | Volatile | One-year price volatility — 58.7% |
| Operating pressure | 23 | Normal | Stable | Costs outgrowing revenue — -0.8 percentage points |
| Cash conversion | 87 | Acute | Easing | Capital spending against operating cash — 5.16x |
| Leverage and coverage | 81 | Acute | Easing | Net debt to EBITDA |
| Competitive position | 74 | Stretched | Stable | Operating-margin gap against peers — -18.9 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.